The role of VEGF and KDR polymorphisms in moyamoya disease and collateral revascularization by 源��룞�꽍
The Role of VEGF and KDR Polymorphisms in Moyamoya
Disease and Collateral Revascularization
Young Seok Park1, Young Joo Jeon2, Hyun Seok Kim2, Kyu Young Chae3, Seung-Hun Oh4, In Bo Han1,
Hyun Sook Kim4, Won-Chan Kim4, Ok-Joon Kim4, Tae Gon Kim1, Joong-Uhn Choi1, Dong-Seok Kim5*,
Nam Keun Kim3*
1Department of Neurosurgery, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, South Korea, 2 Institute for Clinical Research, CHA Bundang
Medical Center, CHA University School of Medicine, Seongnam, South Korea, 3Department of Pediatrics, CHA Bundang Medical Center, CHA University School of
Medicine, Seongnam, South Korea, 4Department of Neurology, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, South Korea, 5Department
of Pediatric Neurosurgery, Severance Hospital, Brain Korea 21 Project for Medical Science, Brain Research Institute, Yonsei University College of Medicine, Seoul, Korea
Abstract
We conducted a case-control study to investigate whether vascular endothelial growth factor (VEGF 22578, 21154, 2634,
and 936) and kinase insert domain containing receptor (KDR 2604, 1192, and 1719) polymorphisms are associated with
moyamoya disease. Korean patients with moyamoya disease (n = 107, mean age, 20.9615.9 years; 66.4% female) and 243
healthy control subjects (mean age, 23.0616.1 years; 56.8% female) were included. The subjects were divided into pediatric
and adult groups. Among the 64 surgical patients, we evaluated collateral vessel formation after 2 years and divided
patients into good (collateral grade A) or poor (collateral grade B and C) groups. The frequencies and distributions of four
VEGF (22578, 21154, 2634, and 936) and KDR (2604, 1192, and 1719) polymorphisms were assessed from patients with
moyamoya disease and compared to the control group. No differences were observed in VEGF 22578, 21154, 2634, and
936 or KDR 2604, 1192, and 1719 polymorphisms between the control group and moyamoya disease group. However, we
found the 2634CC genotype occurred less frequently in the pediatric moyamoya group (p= 0.040) whereas the KDR
2604C/1192A/1719T haplotype increased the risk of pediatric moyamoya (p= 0.024). Patients with the CC genotype of VEGF
2634 had better collateral vessel formation after surgery. Our results suggest that the VEGF 2634G allele is associated with
pediatric moyamoya disease and poor collateral vessel formation.
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Introduction
Although many studies have investigated the etiology of
moyamoya disease, unsatisfactory progress has been made.
Moyamoya disease etiology may be idiopathic, environmental,
or genetic. The search for genetic loci linked to moyamoya disease
has uncovered associations with chromosomes 3, 6, 7, 8, and 17
and the HLA haplotype [1–8], but relevant genes have not been
identified [9]. Recent linkage analyses from East Asian families
with moyamoya disease demonstrated a linkage of 17q25.3 with
the disease at a locus that is 21480 bp from the transcription site
of the Raptor gene. However, an allele of this gene was not
detected in samples from Caucasian patients with this disease [10].
Vascular endothelial growth factor (VEGF) is involved in
vasculogenesis and vascular permeability in various intracranial
lesions [11]. In ischemic disease, cerebral angiogenesis is caused by
the release of VEGF [12,13]. VEGF affects vasculogenesis,
endothelial cell proliferation and migration, vascular permeability,
and stromal degradation through the activation of proteolytic
enzymes that are involved in angiogenesis [14,15]. VEGF binds its
receptor tyrosine kinases, VEGF receptor-1 and VEGF receptor-2
(also known as kinase insert domain containing receptor, or KDR)
but KDR is the key receptor mediating angiogenesis [16] and is
essential for endothelial cell survival and integrity [17].
Although excess VEGF in moyamoya disease has been
demonstrated [11,18] and the association is convincing, the
specific role for VEGF remains unclear. Therefore, we studied the
relationship of VEGF and KDR polymorphisms and moyamoya
disease. VEGF is a major angiogenic factor and a prime regulator
of endothelial cell proliferation [19]. The gene that encodes VEGF
is located on chromosome 6 and is comprised of a 14-kb coding
region with eight exons and seven introns [20]. VEGF is activated
transcriptionally and posttranscriptionally by hypoxia in tumor
necrosis and in various models of ischemia [21,22]. Ischemia
stimulates VEGF expression in the brain suggesting that it may be
important for the vascular response to cerebral ischemia
[23,24,25]. Several single nucleotide polymorphisms (SNPs) have
been described in the VEGF gene (National Center for Biotech-
nology Information, Gene association no: NT 007592). The VEGF
gene includes at least 4 relatively common polymorphisms that
may influence VEGF expression: 22578C.A (rs699947),
21154G.A (rs1570360), 2634G.C (rs2010963), and 936C.T
(rs3025039) [26,27,28].
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Three of these polymorphisms are located in the promoter
region at 22578, 21154, and 2634 relative to the translation
start site. The 22578A, 21154A, and 2634G alleles are all
associated with decreased VEGF expression [26,27]. In addition to
promoter region polymorphisms, the T allele of the common
936C.T polymorphism in the 39-untranslated region is also
associated with significantly decreased serum VEGF levels [28].
Recently, several SNPs of the VEGF gene have been associated
with cancer risk and prognosis [29], as well as coronary arterial
disease [30]. Moreover, KDR2604C, 1192A, and 1719A alleles of
chromosome 4 were associated with decreased VEGF binding
activity and coronary artery disease [31]. These results indicate the
importance of VEGF-KDR signaling in human disease.
To our knowledge, no previous study has evaluated both KDR
and VEGF polymorphisms with moyamoya disease and collateral
vessel formation after surgery. The aim of present study was to
evaluate the frequencies of the VEGF 22578C.A, 21154G.A,
2634G.C, and 936C.T and KDR 2604T.C (rs2071559),
1192G.A (rs2305948), and 1719T.A (rs1870377) polymor-
phisms in Korean patients with moyamoya disease in an effort
to determine the relationship of these polymorphisms with
moyamoya disease.
Methods
Subjects
One hundred seven consecutive Korean patients with moya-
moya disease [mean age, 20.9615.9 years; 71 females (66.4%), 36
males (33.6%)] were recruited for this study. Moyamoya disease
was defined as the presence of clinical ischemic or hemorrhagic
symptoms in combination with vascular lesions in magnetic
resonance imaging (MRI) or magnetic resonance angiography
(MRA).
The control group was comprised of 243 healthy subjects [mean
age, 23.0616.1 years; 138 female (56.8%); 105 male (43.2%)]
from the same geographic region as the moyamoya patients. These
age- and sex-matched subjects were recruited from outpatient
clinics at Severance Hospital (Seoul, Korea) and CHA Bundang
Medical Center (Seongnam, Korea).
Moyamoya disease has a bimodal pattern of incidence so we
divided the patients into pediatric (,18 years) and adult ($18
years) groups. We further divided the moyamoya patients into
ischemic or hemorrhagic groups based on clinical and MRI
findings. We performed indirect bypass surgery in 64 patients and
direct superficial temporal artery to middle cerebral artery bypass
plus encephalo-duro-arterio-myo-synangiosis (STA-MCA plus
EDAMS) in one patient. We graded newly developed collateral
vessels according to the method of Matsushima et al. [32]. Briefly,
Grade A represented synangiosis-induced filling of greater than
Table 1. Demographic characteristics between controls and moyamoya patients.
Characteristic Control (n = 243)
Moyamoya
(n=107) P*
Ischemic
moyamoya
(n=92)
Hemorrhagic
moyamoya
(n =15) P*
Number of subjects
,18 years 102 (42.0) 56 (52.3) 54 (58.7) 2 (13.3)
$18 years 141 (58.0) 51 (47.7) 38 (41.3) 13 (86.7)
Age (means6SD)
,18 years 7.7164.05 7.9864.13 0.920 8.1164.12 4.5063.54 NA
$18 years 36.72610.05 34.98611.29 0.248 34.63611.45 36.00611.21 0.689
Sex [male, n(%)]
,18 years 54 (52.9) 22 (39.3) 0.100 21 (38.9) 1 (50.0) 1.000{
$18 years 51 (21.0) 14 (27.5) 0.260 12 (31.6) 2 (15.4) 0.472{
Collateral vessel formation score (n = 64)
0 – 2
1 – 22
2 – 40
*P values were calculated using the Mann-Whitney test for continuous data and x2-test for categorical data.
{Fisher’s exact test. NA; not applicable.
doi:10.1371/journal.pone.0047158.t001
Figure 1. Linkage disequilibrium(LD) of VEGF and KDR
polymorphisms. There was strong LD between 21154G.A (rs
1570460) and 2634G.C (rs2010963) (D9 = 0.92), 22578C.A (rs
699947)and 1154G.A (rs1570360) (D9=0.89). There was strong LD
between 1719T.A(rs1870377) and 1192G.A (rs2305948) (D9= 0.79).
doi:10.1371/journal.pone.0047158.g001
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two-thirds of MCA circulation, Grade B represented between one-
third and two-thirds, and Grade C represented less than one-third.
We further divided the 64 indirect bypass surgical patients by
collateral vessel formation after 2 years into good (collateral grade
A) and poor (collateral grade B, C) using MRA. Table 1 shows the
demographic characteristics of the moyamoya patients and control
subjects.
All participants gave informed written consent prior to
enrollment in the study. The institutional review boards of
Severance Hospital (4-2008-0308) and CHA Bundang Medical
Center (PBC09-103) approved this study.
VEGF Genotyping
We investigated four relevant single nucleotide polymorphism
(SNP) candidates in the VEGF gene. We used the G-DEX blood
extraction kit (iNtRON Biotechnology, Inc., Seongnam, South
Korea) according to the manufacturer’s instructions for DNA
extraction. We obtained all SNP sequences from the HapMap
database (www.hapmap.org) [33]. The VEGF -2578C.A, -
1154G.A, -634G.C, and 936C.T polymorphisms were
analyzed by polymerase chain reaction–restriction fragment length
polymorphism (PCR-RFLP) method.
We used following primers: VEGF 22578C.A polymorphism,
forward 59-GGA TGG GGC TGA CTA GGT AAG-39 and
reverse 59-AGC CCC CTT TTC CTC CAA C-39, that amplifies
a 308 bp (C allele) or 326 bp (A allele) product; VEGF
21154G.A polymorphism, forward 59-CGC GTG TCT CTG
GAC AGA GTT TCC-39 and reverse 59-CGG GGA CAG GCG
AGC TTC AG-39, that amplifies a 173 bp product; VEGF
2634G.C polymorphism, forward 59-CAG GTC ACT CAC
TTT GCC CCG GTC-39 and reverse 59-GCT TGC CAT TCC
CCA CTT GAA TCG-39, that amplifies a 204 bp product; and
VEGF 936C.T polymorphism, forward 59-AAG GAA GAG
GAG ACT CTG CGC AGA GC-39 and reverse 59-TAA ATG
TAT GTA TGT GGG TGG GTG TGT CTA CAG G-39, that
amplifies a 208 bp fragment.
The VEGF 22578C.A and 2634G.C polymorphisms were
identified by digesting the PCR product with the restriction
endonuclease AvaII (New England Biolabs, Beverly, MA, USA).
The VEGF 21154G.A polymorphism was identified by digesting
the PCR product with the restriction endonuclease MnlI (New
England Biolabs). The VEGF 936C.T polymorphism was
identified by digesting the PCR product with the restriction
endonuclease NlaIII (New England Biolabs). All restriction digests
were performed at 37uC for 16 h.
KDR Genotyping
We identified 3 well-known SNPs in the KDR gene, including
one in the promoter region (2604) and two in the coding region
(1192 and 1719). All SNP sequences were obtained from the
HapMap database (http://www.hapmap.org) [33]. We used
previously described primers and PCR-RFLP conditions for
Table 2. The frequencies of the VEGF 22578C.A, 21154G.A, 2634G.C, and 936C.T polymorphisms between control subjects
and patients with moyamoya disease.
Characteristics Controls (n=243, %) Moyamoya patients (n =107, %) AOR (95% CI) P*
VEGF 22578C.A
CC 128 (52.7) 62 (57.9) 1.000 (reference)
CA 99 (40.7) 36 (33.6) 0.769 (0.470–1.258) 0.296
AA 16 (6.6) 9 (8.4) 1.188 (0.491–2.873) 0.702
Dominant (CC vs. CA+AA) 0.827 (0.520–1.315) 0.422
Recessive (CC+CA vs. AA) 1.296 (0.547–3.072) 0.556
VEGF–1154G.A
GG 173 (71.2) 80 (74.8) 1.000 (reference)
GA 62 (25.5) 25 (23.4) 0.873 (0.510–1.496) 0.622
AA 8 (3.3) 2 (1.9) 0.517 (0.106–2.519) 0.414
Dominant (GG vs. GA+AA) 0.834 (0.495–1.405) 0.495
Recessive (GG+GA vs. AA) 0.546 (0.113–2.653) 0.454
VEGF 2634G.C
GG 90 (37.0) 37 (34.6) 1.000 (reference)
GC 103(42.4) 48 (44.9) 1.127 (0.666–1.906) 0.655
CC 50 (20.6) 22 (20.6) 1.083 (0.575–2.042) 0.804
Dominant (GG vs. GC+CC) 1.124 (0.695–1.817) 0.634
Recessive (GG+GC vs. CC) 1.024 (0.579–1.811) 0.934
VEGF 936C.T
CC 172 (70.8) 67 (62.6) 1.000 (reference)
CT 64 (26.3) 37 (34.6) 1.530 (0.926–2.529) 0.097
TT 7 (2.9) 3 (2.8) 1.230 (0.301–5.027) 0.773
Dominant (CC vs. CT+TT) 1.484 (0.912–2.416) 0.112
Recessive (CC+CT vs. TT) 1.079 (0.270–4.313) 0.915
*Adjusted by age and gender. AOR, adjusted odds ratio. CI, confidence interval.
doi:10.1371/journal.pone.0047158.t002
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KDR polymorphism analyses [31]. For SNP 2604, two DNA
fragments (174 bp and 116 bp) were observed for the C allele and
one band (290 bp) was produced for the T allele. For the 1192
polymorphism, two DNA fragments (30 bp and 232 bp) indicated
the A allele and one band (252 bp) was produced for the G allele.
For SNP 1719, two DNA fragments (191 bp and 213 bp) were
observed for the A allele and one band (404 bp) was produced for
the T allele. The genotyping reproducibility was confirmed by bi-
directional sequencing of 400 randomly selected samples.
Measurement of Plasma Total Homocysteine (tHcy), Folic
Acid (FA), and Vitamin B12 (VB12)
Blood was collected from moyamoya patients into a tube
containing anticoagulant 12 hours after a meal. The tube was
centrifuged for 15 min at 10006g, and the plasma was separated.
The concentration of tHcy (n= 37, 10.1862.81 mmol/L) in the
plasma was measured by fluorescent polarizing immunoassay
(FPIA) with IMx (Abbott Laboratories, Chicago, IL, USA). The
plasma concentration of FA (n= 30, 10.2563.50 ng/ml) and
VB12 (n = 35, 848.066319.22 pg/ml) was determined using a
radioassay kit (ACS 180; Bayer, Tarrytown, NY, USA).
Measurement of Whole Blood Nitric Oxide (NO)
Blood was collected from moyamoya patients into a tube
containing anticoagulant 12 hours after a meal. NO production
was evaluated by determining the circulating levels of nitrosyl-
hemoglobin complexes. In the present study, the paramagnetic
properties of nitrosyl-heme adducts were used to detect whole
blood NO-hemoglobin derivatives (n = 33, 5.3066.93 arbitrary
unit [AU]) by electron paramagnetic resonance (EPR) spectros-
copy.
Statistical Analyses
To analyze the demographic characteristics of moyamoya
disease, we used the Mann–Whitney and chi-square (x2) tests for
continuous and categorical data, respectively. The associations
among pediatric and adult patients were estimated by computing
the odds ratios (ORs) and 95% confidence intervals (CIs) using
Fisher’s exact test. The adjusted odds ratios (AORs) for VEGF and
KDR polymorphisms were calculated using multiple logistic
regression analyses using gender and age. The genotype distribu-
tion of each polymorphism was expected under Hardy-Weinberg
equilibrium. Statistical analyses were performed using GraphPad
Prism 4.0 (GraphPad Software, Inc., San Diego, CA, USA) and
StatsDirect software (version 2.4.4; StatsDirect Ltd., Altrincham,
UK). Haplotype analyses were performed using HAPSTAT
(version 3.0; University of North Carolina, Chapel Hill, NC,
USA) and Haploview 4.2 (Broad Institute, Cambridge, MA, USA).
StatsDirect Statistical Software (Version 2.4.4; StatsDirect Ltd,
Altrincham, UK) was used to calculate the adjusted OR and 95%
CI. The linkage disequilibrium between loci was measured using
the absolute value of Lewontin’s D [34].
Results
Figure 1 shows the linkage disequilibrium of VEGF and KDR
polymorphisms from the present study. A comparison of genotype
frequencies between moyamoya patients and control subjects of
the VEGF 22578C.A, 21154G.A, 2634G.C, and 936C.T
polymorphisms and the KDR 2604T.C, 1192G.A, and
1719T.A polymorphisms is shown in Table 2. There were no
statistically significant differences between moyamoya patients and
controls in any of the polymorphisms evaluated (Tables 2 and 3).
In subgroup analyses (Tables 4 and 5), the CC genotype of the
VEGF 2634 was less frequent in pediatric moyamoya disease
(p=0.040; CC vs. GG) and comparison with the GG+GC
Table 3. The frequencies of the KDR 2604T.C, 1192G.A, and 1719T.A polymorphisms between control subjects and patients
with moyamoya disease.
Characteristics Controls (n=243, %) Moyamoya patients (n =107, %) AOR (95% CI) P*
KDR 2604T.C
TT 113 (46.5) 47 (43.9) 1.000 (reference)
TC 108 (44.4) 50 (46.7) 1.131 (0.698–1.833) 0.617
CC 22 (9.1) 10 (9.3) 1.102 (0.482–2.517) 0.818
Dominant (CC vs. CA+AA) 1.128 (0.710–1.792) 0.609
Recessive (CC+CA vs. AA) 1.039 (0.470–2.296) 0.925
KDR 1192G.A
GG 186 (76.5) 80 (74.8) 1.000 (reference)
GA 52 (21.4) 22 (20.6) 0.994 (0.563–1.754) 0.983
AA 5 (2.1) 5 (4.7) 2.140 (0.596–7.693) 0.244
Dominant (GG vs. GA+AA) 1.101 (0.646–1.875) 0.725
Recessive (GG+GA vs. AA) 2.139 (0.597–7.665) 0.243
KDR 1719T.A
TT 46 (18.9) 26 (24.3) 1.000 (reference)
TA 114 (46.9) 45 (42.1) 0.764 (0.417–1.401) 0.384
AA 83 (34.2) 36 (33.6) 0.799 (0.427–1.495) 0.482
Dominant (TT vs. TA+AA) 0.775 (0.446–1.346) 0.365
Recessive (TT+TA vs. AA) 0.997 (0.613–1.620) 0.989
*Adjusted by age and gender. AOR, adjusted odds ratio. CI, confidence interval.
doi:10.1371/journal.pone.0047158.t003
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genotype was also significantly different in pediatric moyamoya
patients. In the adult subgroup, the VEGF 2634CC genotype was
more frequent in moyamoya disease (p=0.024; CC vs. GG). The
frequencies of the KDR polymorphisms in both the pediatric and
adult subgroups were not significantly different.
We conducted haplotype analyses of the VEGF and KDR
polymorphisms (Table 6). The C-G-C-C haplotype (VEGF
22578/21154/2634/936) in pediatric moyamoya patients was
significantly different. In addition, the C-A-T haplotype (KDR
2604/1192/1719) increased the risk of pediatric moyamoya. In
adult moyamoya, the A-A-G-C haplotype (VEGF 22578/21154/
2634) was significantly different whereas other haplotypes were
not. We have estimated and provided several haplotype frequen-
cies in Table 6.
We performed indirect bypass surgery in 64 patients. The
genotypes containing the VEGF 2634C allele had better collateral
vessel formation after surgery whereas 2634GG was associated
with poor collateral grade (Table 7). We also investigated the
haplotype frequency differences related to collateral grades.
However, there were no statistical differences (Table S1). Our
results potentially implicate the VEGF 2634G.C polymorphism
in the development of collateral vessel formation in moyamoya
disease. The other VEGF and KDR polymorphisms we studied did
not exhibit statistically significant differences in collateral vessel
formation.
To assess the clinical significance of the VEGF and KDR
polymorphisms, we surveyed the association between the studied
polymorphisms and various vascular risk factors (tHcy, FA, VB12,
and NO). Blood tHcy, FA, VB12, and NO are essential for
vascular homeostasis regulation [35]. There were no significant
distinctions according to VEGF polymorphisms but the KDR
2604C (p=0.017) and 1192A (p=0.032) alleles were linked to
decreased NO levels (Table S2). The association of the KDR 2604
and 1192 polymorphisms with NO levels suggests that KDR
haplotypes containing 2604C or 1192A may adversely affect
vascular homeostasis.
Table 4. The frequency of the VEGF polymorphisms according to age.
Age ,18 years Age $18 years
Characteristics
Controls
(n =102, %)
Moyamoya
(n=56, %) AOR (95% CI) P*
Controls
(n =141, %)
Moyamoya
(n=51, %) AOR (95% CI) P*
VEGF 22578C.A
CC 57 (55.9) 29 (51.8) 1.000 (reference) 71 (50.4) 33 (64.7) 1.000 (reference)
CA 42 (41.2) 22 (39.3) 1.100 (0.548–2.206) 0.789 57 (40.4) 14 (27.5) 0.539 (0.261–1.113) 0.095
AA 3 (2.9) 5 (8.9) 3.191 (0.696–14.631) 0.135 13 (9.2) 4 (7.8) 0.669 (0.200–2.242) 0.514
Dominant (CC vs.
CA+AA)
1.246 (0.638–2.433) 0.519 0.543 (0.277–1.063) 0.075
Recessive (CC+CA
vs. AA)
3.044 (0.686–13.499) 0.143 0.777 (0.239–2.525) 0.674
VEGF 21154G.A
GG 77 (75.5) 44 (78.6) 1.000 (reference) 109 (77.3) 36 (70.6) 1.000 (reference)
GA 22 (21.6) 9 (16.1) 1.614 (0.755–3.449) 0.217 30 (21.3) 13 (25.5) 0.391 (0.160–0.957) 0.040
AA 3 (2.9) 3 (5.4) 0.695 (0.067–7.200) 0.760 2 (1.4) 2 (3.9) 0.445 (0.049–4.029) 0.472
Dominant (GG vs.
GA+AA)
1.522 (0.729–3.178) 0.264 0.395 (0.169–0.923) 0.032
Recessive (GG+GA
vs. AA)
0.608 (0.061–6.044) 0.671 0.517 (0.058–4.589) 0.554
VEGF 2634G.C
GG 34 (33.3) 24 (42.9) 1.000 (reference) 56 (39.7) 13 (25.5) 1.000 (reference)
GC 46 (45.1) 27 (48.2) 0.813 (0.398–1.664) 0.571 57 (40.4) 21 (41.2) 1.715 (0.771–3.816) 0.186
CC 22 (21.6) 5 (8.9) 0.301 (0.096–0.946) 0.040 28 (19.9) 17 (33.3) 2.698 (1.137–6.403) 0.024
Dominant (GG vs.
GC+CC)
0.644 (0.236–1.273) 0.206 2.016 (0.979–4.152) 0.057
Recessive (GG+GC
vs. CC)
0.334 (0.117–0.955) 0.041 2.087 (1.014–4.295) 0.046
VEGF 936C.T
CC 76 (74.5) 38 (67.9) 1.000 (reference) 96 (68.1) 31 (60.8) 1.000 (reference)
CT 24 (23.5) 18 (32.1) 1.580 (0.756–3.303) 0.224 41 (29.1) 17 (33.3) 1.322 (0.652–2.681) 0.438
TT 2 (2.0) 0 (0.0) NA NA 4 (2.8) 3 (5.9) 2.562 (0.525–12.506) 0.245
Dominant (CC vs.
CT+TT)
1.405 (0.681–2.900) 0.357 1.378 (0.702–2.702) 0.351
Recessive (CC+CT
vs. TT)
2.207 (0.472–10.328) 0.315
*Adjusted by age and gender. NA; not applicable. AOR, adjusted odds ratio. CI, confidence interval.
doi:10.1371/journal.pone.0047158.t004
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Table 5. The frequency of the KDR polymorphisms according to age.
Age ,18 years Age $18 years
Characteristics
Controls
(n =102, %)
Moyamoya
(n=56, %) AOR (95% CI) P*
Controls
(n =141, %)
Moyamoya
(n=51, %) AOR (95% CI) P*
KDR 2604T.C
CC 54 (52.9) 25 (44.6) 1.000 (reference) 59 (41.8) 22 (43.1) 1.000 (reference)
CA 40 (39.2) 27 (48.2) 1.413(0.711–2.808) 0.324 68 (48.2) 23 (45.1) 0.929 (0.467–1.847) 0.833
AA 8 (7.8) 4 (7.1) 1.096(0.298–4.031) 0.890 14 (9.9) 6 (11.8) 1.141 (0.388–3.356) 0.811
Dominant (CC vs.
CA+AA)
1.350(0.697–2.616) 0.374 0.951 (0.495–1.826) 0.879
Recessive (CC+CA vs.
AA)
0.889(0.251–3.143) 0.855 1.198 (0.433–3.320) 0.728
KDR 1192G.A
GG 20 (19.6) 16 (28.6) 1.000 (reference) 26 (18.4) 10 (19.6) 1.000 (reference)
GA 47 (46.1) 22 (39.3) 0.572 (0.246–1.323) 0.193 67 (47.5) 23 (45.1) 1.082 (0.440–2.664) 0.864
AA 35 (34.2) 18 (32.1) 0.654 (0.232–1.572) 0.342 48 (34.0) 18 (35.3) 0.965 (0.382–2.435) 0.940
Dominant (GG vs.
GA+AA)
0.611 (0.284–1.313) 0.207 1.003 (0.440–2.286) 0.994
Recessive (GG+GA vs.
AA)
0.927 (0.460–1.869) 0.833 1.069 (0.543–2.103) 0.848
KDR 1719T.A
TT 77 (75.5) 44 (78.6) 1.000 (reference) 109 (77.3) 36 (70.6) 1.000 (reference)
TA 22 (21.6) 9 (16.1) 0.739 (0.310–1.762) 0.495 30 (21.3) 13 (25.5) 1.283 (0.602–2.734) 0.518
AA 3 (2.9) 3 (5.4) 1.848 (0.349–9.773) 0.470 2 (1.4) 2 (3.9) 3.003 (0.403–22.390) 0.283
Dominant (TT vs.
TA+AA)
0.877 (0.398–1.934) 0.746 1.378 (0.667–2.846) 0.386
Recessive (TT+TA vs.
AA)
2.026 (0.382–10.736) 0.407 2.675 (0.362–19.768) 0.335
*Adjusted by age and gender. NA; not applicable. AOR, adjusted odds ratio. CI, confidence interval.
doi:10.1371/journal.pone.0047158.t005
Table 6. Haplotype frequencies of the VEGF and KDR polymorphisms according to age.
Age ,18 years Age $18 years
Characteristics
Controls
(n =102, %)
Moyamoya
(n=56, %) OR (95% CI) P*
Controls
(n =141, %)
Moyamoya
(n =51, %) OR (95% CI) P*
VEGF 22578/21154/2634/936
CGCC 0.3502 0.2331 0.566 (0.335–0.957) 0.041 0.3251 0.4350 1.594 (1.001–2.540) 0.053
CGGC 0.2894 0.3561 1.365 (0.836–2.231) 0.254 0.2360 0.2047 0.842 (0.484–1.465) 0.584
AAGC 0.1234 0.1361 1.107 (0.557–2.199) 0.860 0.1471 0.0406 0.250 (0.087–0.718) 0.006
CGCT 0.0910 0.0578 0.551 (0.213–1.423) 0.277 0.0708 0.0741 0.976 (0.400–2.382) 1.000
AGGC 0.0840 0.0648 0.733 (0.295–1.826) 0.658 0.1085 0.0587 0.511 (0.207–1.265) 0.171
CGGT 0.0233 0.0372 1.474 (0.388–5.606) 0.726 0.0656 0.0620 0.926 (0.357–2.403) 1.000
AGGT 0.0152 0.0532 3.792 (0.930–15.470) 0.073 0.0189 0.0310 1.696 (0.398–7.231) 0.440
CAGC 0.0109 0.0221 1.836 (0.255–13.220) 0.617 NA NA NA NA
AAGT NA NA NA NA 0.0149 0.0368 2.866 (0.703–11.680) 0.216
KDR 2604/1192/1719
TGA 0.4141 0.3786 0.857 (0.534–1.376) 0.550 0.3624 0.3736 1.048 (0.655–1.675) 0.845
TGT 0.2187 0.2688 1.293 (0.758–2.204) 0.407 0.2551 0.2337 0.897 (0.528–1.525) 0.689
CGA 0.1325 0.1393 1.093 (0.561–2.128) 0.864 0.1990 0.1919 0.984 (0.557–1.740) 0.957
CGT 0.0974 0.0794 0.804 (0.353–1.831) 0.687 0.0630 0.0341 0.444 (0.128–1.542) 0.190
TAT 0.0773 0.0402 0.549 (0.196–1.541) 0.346 0.0421 0.0495 1.160 (0.398–3.378) 0.786
CAT 0.0330 0.0938 3.065 (1.153–8.148) 0.024 0.0618 0.1042 1.884 (0.851–4.173) 0.113
*P-values after 10,000 permutation test. NA; not applicable. OR, odds ratio. CI, confidence interval.
doi:10.1371/journal.pone.0047158.t006
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Discussion
In this study, we found VEGF or KDR polymorphisms influence
moyamoya disease in subgroup analyses as well as the formation of
revascularization after bypass surgery. VEGF is involved in
vasculogenesis in different intracranial lesions [11], is an endo-
thelial cell mitogen that induces transient vascular leakage, and a
potent angiogenic factor [36]. VEGF promotes angiogenesis in
cerebral ischemia [11,37] and causes pathologic vessel formation
[12].
Table 7. Comparison of the VEGF and KDR genotype frequencies according to collateral vessel formation score.
Characteristics Collateral grade A (n=40)
Collateral grade B
and C (n=24) AOR (95% CI) P*
VEGF 22578C.A
CC 20 (50.0) 13 (54.2) 1.000 (reference)
CA 18 (45.0) 7 (29.2) 0.615 (0.200–1.893) 0.397
AA 2 (5.0) 4 (16.7) 3.060 (0.473–19.816) 0.241
Dominant (CC vs. CA+AA) 0.867 (0.313–2.408) 0.785
Recessive (CC+CA vs. AA) 3.757 (0.625–22.590) 0.148
VEGF 21154G.A
GG 27 (67.5) 17 (70.8) 1.000 (reference)
GA 12 (30.0) 6 (25.0) 0.841 (0.253–2.796) 0.777
AA 1 (2.5) 1 (4.2) 1.475 (0.082–26.410) 0.792
Dominant (GG vs. GA+AA) 0.926 (0.297–2.886) 0.895
Recessive (GG+GA vs. AA) 1.565 (0.090–27.244) 0.759
VEGF 2634G.C
GG 11 (27.5) 13 (54.2) 1.000 (reference)
GC 22 (55.0) 7 (29.2) 0.252 (0.076–0.837) 0.024
CC 7 (17.5) 4 (16.7) 0.284 (0.045–1.780) 0.179
Dominant (GG vs. GC+CC) 0.286 (0.095–0.859) 0.026
Recessive (GG+GC vs. CC) 0.857 (0.215–3.412) 0.827
VEGF 936C.T
CC 27 (67.5) 16 (66.7) 1.000 (reference)
CT 13 (32.5) 8 (33.3) 1.069 (0.357–3.206) 0.905
TT 0 (0.0) 0 (0.0) NA NA
Dominant (CC vs. CT+TT) 1.069 (0.357–3.206) 0.905
Recessive (CC+CT vs. TT) NA NA
KDR 2604T.C
TT 17 (42.5) 11 (45.8) 1.000 (reference)
TC 19 (47.5) 12 (50.0) 0.950 (0.325–2.778) 0.926
CC 4 (10.0) 1 (4.2) 0.370 (0.035–3.962) 0.411
Dominant (TT vs. TC+CC) 0.840 (0.298–2.367) 0.741
Recessive (TT+TC vs. CC) 0.346 (0.035–3.409) 0.363
KDR 1192G.A
GG 30 (75.0) 16 (66.7) 1.000 (reference)
GA 8 (20.0) 7 (29.2) 1.381 (0.401–4.758) 0.609
AA 2 (5.0) 1 (4.2) 0.843 (0.063–11.263) 0.897
Dominant (GG vs. GA+AA) 1.355 (0.420–4.375) 0.612
Recessive (GG+GA vs. AA) 0.664 (0.053–8.390) 0.752
KDR 1719T.A
TT 10 (25.0) 7 (29.2) 1.000 (reference)
TA 18 (45.0) 9 (37.5) 0.786 (0.219–2.824) 0.712
AA 12 (30.0) 8 (33.3) 0.886 (0.227–3.462) 0.861
Dominant (TT vs. TA+AA) 0.825 (0.259–2.626) 0.745
Recessive (TT+TA vs. AA) 1.195 (0.398–3.593) 0.751
*Adjusted by age and gender. NA; not applicable. AOR, adjusted odds ratio. CI, confidence interval.
doi:10.1371/journal.pone.0047158.t007
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Moyamoya disease is characterized by the angiographic findings
of arterial stenosis and occlusion of the circle of Willis [38]. It can
lead to transient ischemic attacks or a cerebral infarction pattern in
juveniles [39] and a hemorrhagic stroke pattern in adults [40,41].
Takekawa et al. [18] reported increased VEGF expression in
autopsy specimens from adults with moyamoya disease and
Sakamoto et al. reported that the total meningeal cellularity and
VEGF expression in the moyamoya dura was significantly higher
in moyamoya patients compared to controls [11]. Although
increased VEGF concentrations have been demonstrated in
moyamoya disease [11,18], the specific role of VEGF in moyamoya
genetics remains unclear. We therefore reasoned that mutations
and genetic polymorphisms of the VEGF gene may cause cerebral
ischemia in moyamoya disease.
Vascular endothelial growth factor A (VEGF-A) is a disulfide-
bonded dimeric glycoprotein that is a member of a protein family
that includes VEGF-B, VEGF-C, VEGF-D, and placental growth
factor (PGF). The gene that encodes VEGF-A is located on human
chromosome 6 and comprises a 14-kb coding region with eight
exons. VEGF cellular signaling activity depends on specific
membrane receptors. The receptors include fms like tyrosine
kinase-1 (Flt-1 or VEGFR-1), KDR (also known as VEGFR-2)
[42,43], and Flt-4 (also known as VEGFR-3) [44,45]. VEGF acts
on endothelial cells particularly through Flt-1 and KDR [46,47].
Epidermal growth factor (EGF) arising from hypoxia stimulates
Flt-1 expression and inhibits KDR expression [48].
VEGF binding to KDR activates multiple signaling cascades
that affect angiogenesis as well as endothelial cell survival,
proliferation, and migration. Recently, several SNPs in the VEGF
gene have been linked to cancer risk and prognosis [29] and
coronary arterial disease [30], indicating the importance of the
VEGF-KDR signaling pathway in human disease. Oh et al.
reported the SNP 1719T allele conferred ischemic stroke risk in a
dose dependent manner [49].
Revascularization after bypass surgery and the formation of new
pial vessels may play a role in moyamoya disease. Several studies
have suggested that endogenous VEGF production mediates
compensatory revascularization during various physiological and
pathological processes [37,50,51,52].
In addition, as suggested by the data in our study, VEGF
2634 G.C may be a possible prognostic biomarker after bypass
surgery. Taken together, we can speculate that VEGF polymor-
phisms influence moyamoya disease as well as the formation of
synangiosis-induced collateral vessel after bypass surgery. Al-
though revascularization with pial synangiosis helps ameliorate
ischemic symptoms, some patients progress to cerebral infarction
or hemorrhage, even after surgery. This likely reflects the degree of
synangiosis and is dependent on the genetic characteristics of the
patient. Therefore, VEGF or KDR polymorphisms can be used as
prognostic factors after revascularization surgery.
There are some limitations in correlating VEGF or KDR
polymorphisms with our clinical findings. Our data should be
interpreted with caution because of the relatively small sample
size. Patients require long-term follow up to assess clinical
outcomes and variation in the clinical characteristics of moyamoya
disease makes it difficult to identify specific genes that are
associated with the disease. In addition, moyamoya disease is
characterized by genetic heterogeneity and complex interactions
between genes and other factors. Although there are limitations
with sample size and long-term follow-up clinical findings, it is
important to determine the relationship of VEGF or KDR
polymorphisms with moyamoya disease and collateral vessel
formation after surgery.
In summary, no differences in VEGF 22578, 21154, 2634,
and 936 or KDR 2604, 1192, and 1719 polymorphisms were
observed between total moyamoya disease patients and control
subjects. However, in subgroup analyses, we found that the CC
genotype in VEGF 2634 occurred less frequently in pediatric
patients (p=0.040) and occurred more often in adult moyamoya
patients (p=0.024). The genotypes including the VEGF 2634C
allele had better collateral vessel formation after surgery. In
addition, the C-G-C-C (VEGF 22578/21154/2634/936) hap-
lotype and the C-A-T (KDR -604/1192/1719) haplotype in
pediatric patients, as well as the A-A-G-C (VEGF 22578/
21154/2634/936) in adult moyamoya patients, had significant
differences. Therefore, these results suggest that VEGF or KDR
polymorphisms influence moyamoya disease as well as the
formation of synangiosis-induced collateral vessel after bypass
surgery.
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